Cost-Effectiveness Analysis of the High-Dose Trivalent Influenza Vaccine in the Elderly Population in Italy
The findings suggest that the high-dose vaccine may improve health outcomes while reducing healthcare costs in people aged 65 and over in Italy.
Eight vaccines linked to a lower risk of dementia
A growing body of research is beginning to reveal the impact that regular routine vaccines could be having on the likelihood of conditions like dementia.
Cardiovascular health: MEPs respond to EU Safe Hearts Plan
On Wednesday, Parliament’s Public Health Committee adopted its response to the EU’s first ever cardiovascular health plan.
Interview: The evidence linking respiratory infections to cardiovascular disease is strong and growing
Prof Colin Russell, ESWI Chair and Co-Chair of the Steering Group on Prevention of Respiratory Infections, explains how a new Council Recommendation could enhance preventative health for at-risk groups.
Summary Report: IDC Stakeholder Community Meeting - 10 June 2026, Brussels
Key takeaways and next steps from the first in-person meeting of the IDC
ESWI Activity Report for 2025
Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients
In two open-label trials, nirmatrelvir–ritonavir did not reduce the incidence of hospitalization or death among vaccinated higher-risk participants with SARS-CoV-2 infection.
Recombinant vs Standard Influenza Vaccine in Adults With Severe Obesity: A Randomized Clinical Trial
In adults living with severe obesity, RIV elicited stronger short-term humoral immune responses than an egg-based standard-dose vaccine, suggesting potential additional benefit for influenza prevention in this vulnerable population.
